Phase 2 Malignant Neoplasm trials recruiting now
All Malignant Neoplasm trials, every phase
7
Phase 2 recruiting
Other phases for Malignant Neoplasm
Phase 2 Malignant Neoplasm trials
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
- DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Common questions
What does Phase 2 mean?
Is this list complete?
No. For the full record, search ClinicalTrials.gov.